GHRH (Somatoliberin): The Hormone Behind the Analogs

Growth hormone releasing hormone — GHRH, also called somatoliberin or somatorelin — is the hypothalamic peptide that instructs the pituitary to release growth hormone. It is not a therapy in its native form; it is the biological original that sermorelin, tesamorelin and CJC-1295 were all engineered from.

This guide situates GHRH within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.

What is GHRH?

GHRH is a 44-amino-acid peptide produced in the arcuate nucleus of the hypothalamus and delivered to the anterior pituitary through the hypophyseal portal circulation. There it binds the GHRH receptor on somatotroph cells and triggers both the synthesis and the release of growth hormone.

Its biological activity resides almost entirely in the first 29 amino acids. That fragment, GHRH(1-29), retains full potency — a fact of considerable practical importance, because it is exactly what sermorelin is.

How the axis is actually regulated

Growth hormone release is not controlled by a single signal but by an interplay of three. GHRH stimulates release. Somatostatin, also hypothalamic, inhibits it. Ghrelin, acting at a separate receptor, amplifies it.

The interaction between GHRH and somatostatin produces the defining feature of the axis: growth hormone is secreted in pulses, not continuously, with the largest pulses occurring during slow-wave sleep. Between pulses, levels fall to near-undetectable.

This pulsatility is not incidental. Tissue responses to growth hormone depend on the pattern of exposure, not merely the total amount — pulsatile and continuous exposure produce measurably different downstream effects on gene expression in the liver and elsewhere. This is the central pharmacologic argument for GHRH analogs over exogenous growth hormone: working through the pituitary preserves the pattern and keeps somatostatin's negative feedback intact, whereas injected growth hormone overrides both.

Why every therapy is an analog

Native GHRH has a plasma half-life of only a few minutes. It is rapidly cleaved by dipeptidyl peptidase-4 (DPP-4) at the second amino acid position, which destroys its activity almost immediately. As a drug it would be unusable.

Each therapeutic version solves this differently. Sermorelin is the GHRH(1-29) active fragment, still short-acting but usable. Tesamorelin adds a trans-3-hexenoyl group that resists DPP-4 cleavage, extending duration — and it is the one agent in this family with FDA approval, for HIV-associated lipodystrophy. CJC-1295 introduces substitutions resisting degradation, with a further variant binding albumin for a substantially longer half-life.

Understanding the parent hormone makes the whole family legible: these are not different drugs so much as different answers to a single pharmacokinetic problem.

Clinical relevance

GHRH itself has been used in diagnostic testing of pituitary function rather than as a treatment. Its clinical importance for most practitioners is conceptual: it explains why GHRH analogs raise growth hormone only in patients with a functioning pituitary, and why they cannot exceed the ceiling that somatostatin feedback imposes.

That ceiling is a genuine safety feature and a genuine limitation, and it is the honest framing for patients: a GHRH analog asks the pituitary to work harder within its normal regulatory limits. It does not override the system. The wider class comparison sits in our growth hormone peptides guide.